Other B-cell lymphoma
The EU has approved 1 indication of 1 drug in other B-cell lymphoma. It needs a biomarker result: CD20 (1).
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| CD20-positive1 | ||||
MabThera | + chemotherapy | 1L advanced | Children and adolescents only; Aged 6 months to less than 18 years old | |
Biomarkers in other B-cell lymphoma
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Rituximab (MabThera)
MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged 6 months to less than 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).